Transgender individuals face unique challenges in cancer deaths screening and prevention, leading to disparities in cancer detection and outcomes compared to cisgender populations1. Despite similar overall cancer incidence rates, transgender people have higher rates of precancerous conditions, indicating potential underdiagnosis and delayed detection2. These disparities are compounded by social stigma, healthcare barriers, and limited provider knowledge, underscoring the urgent need for tailored cancer screening strategies3.
Screening Gaps for Transgender Patients
Cancer screening guidelines for transgender individuals often do not fully address their specific risks, resulting in lower screening rates and later-stage cancer diagnoses45. Transgender women, particularly those on prolonged estrogen therapy, have an elevated breast cancer risk compared to cisgender men, while transgender men retain some breast cancer risk after gender-affirming mastectomy due to residual breast tissue678. However, many screening protocols exclude transgender women despite their increased risk from hormone therapy4.
Human papillomavirus (HPV)-related cancers, such as cervical and anal cancer, are also a significant concern due to higher HPV infection rates in transgender populations9. Transgender men with a cervix often have lower rates of Pap smear screening, partly because of gender dysphoria and discomfort with gendered medical procedures1011. Additionally, transgender individuals have higher rates of tobacco and alcohol use, which contribute to increased cancer risk but are not adequately addressed in prevention efforts12.
Transgender, non-binary, and intersex individuals often must self-advocate to receive appropriate cancer screening, especially those who are Black, Indigenous, or people of color. Improved provider education and inclusive intake forms can reduce this burden and improve health outcomes.16
Screening disparities extend beyond breast and cervical cancer. Transgender women are less likely to receive prostate cancer screening despite retaining a prostate, and transgender populations have lower colorectal and lung cancer screening rates compared to cisgender peers131415. These gaps are influenced by misclassification of gender in medical records and screening programs that rely on binary sex categories1617.
Barriers to cancer screening for transgender patients include stigma, discrimination, gender dysphoria, and lack of provider training in transgender health1819. Many transgender individuals report negative healthcare experiences, leading to avoidance of routine care and screening20. Provider knowledge gaps further exacerbate these disparities, with many clinicians expressing insufficient training and confidence in managing cancer risks in transgender patients21.
- Transgender women on estrogen therapy have increased breast cancer risk compared to cisgender men but lower than cisgender women6722.
- Transgender men retain breast cancer risk post-mastectomy due to residual tissue823.
- Cervical cancer screening rates are lower in transgender men with a cervix, partly due to gender dysphoria and inadequate provider knowledge1011.
- HPV-related cancers are more prevalent in transgender populations, emphasizing the need for vaccination and targeted screening924.
- Tobacco and alcohol use are higher among transgender individuals, increasing cancer risk but often overlooked in prevention strategies1225.
Causes and Solutions for Cancer Disparities
Cancer disparities in transgender populations arise from a complex interplay of biological, social, and systemic factors. Hormone therapy and surgical history influence cancer risk profiles uniquely in transgender individuals26612. For example, estrogen exposure in transgender women may increase breast cancer risk, while testosterone therapy in transgender men can cause cervical epithelium atrophy, complicating cervical cancer screening627.
Social determinants such as stigma, discrimination, and systemic barriers significantly contribute to these disparities2619. Transgender people often face refusal of care, harassment, and lack of gender-affirming providers, which discourages engagement with healthcare systems2024. Psychological distress, including gender dysphoria, further reduces participation in cancer screening11.
💡 Did You Know? Transgender persons may be at higher risk for cancers due to coping mechanisms related to discrimination, stigma, and social isolation1.
A critical barrier is the lack of comprehensive gender identity data in cancer registries and health surveys, limiting accurate risk assessment and guideline development919. Misclassification of sex and gender in medical records leads to inappropriate screening recommendations and missed opportunities for early detection1617. Provider knowledge gaps and insufficient training on transgender health needs exacerbate these issues, with many clinicians lacking confidence in delivering appropriate cancer care to transgender patients2119.
Addressing these disparities requires systemic changes:
- Implement inclusive data collection practices that capture gender identity and anatomy to improve risk assessment and screening guidelines91924.
- Enhance provider education and training focused on transgender health and cancer risks to improve screening recommendations and patient interactions211924.
- Develop patient-centered care models that acknowledge gender diversity, reduce stigma, and accommodate gender dysphoria during screening procedures182028.
- Foster trust through respectful communication, use of inclusive language, and visible signs of LGBTQ+ inclusivity in healthcare settings24.
- Increase access to HPV vaccination and targeted prevention programs addressing tobacco and alcohol use in transgender populations7129.
Transgender individuals also experience higher rates of precancerous conditions, such as colorectal and HPV-related precancers, compared to cisgender people, suggesting underdiagnosis and delayed detection2. Insurance coverage plays a protective role, with private insurance or Medicare associated with lower precancer risk, whereas non-Hispanic Black transgender individuals and those with substantial comorbidities face higher risks229.
Improving cancer outcomes in transgender populations involves not only addressing biological risks but also dismantling social and systemic barriers that hinder screening and early diagnosis. Community engagement and inclusion of transgender voices in healthcare planning are essential to develop effective, culturally competent cancer prevention strategies1624.
- Stigma, discrimination, and psychological distress reduce screening participation261811.
- Lack of gender identity data impedes accurate cancer risk assessment and guideline development919.
- Provider knowledge gaps and insufficient training limit appropriate cancer care for transgender patients2119.
- Inclusive data collection and culturally competent care models can improve screening rates and outcomes1924.
- Insurance coverage disparities affect access to preventive care and cancer screening2.
